CIK 0000879407 · Large accelerated filer
ARROWHEAD PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- ARWR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Sep 30
- Incorporated
- DE
- Entity type
- operating
- EIN
- 460408024
- Phone
- 626-696-4702
- Business address
- 177 E COLORADO BLVD, SUITE 700, PASADENA, CA, 91105
- Former names
- ARROWHEAD RESEARCH CORP, INTERACTIVE GROUP INC, INTERACTIVE INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,186,600
- in 2 filings
Net −$1,186,600. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-03-13 | Anzalone Christopher Richard Chief Executive Officer | Grant or award | +340,000 | 4,113,802 | ||
| 2025-03-13 | Anzalone Christopher Richard Chief Executive Officer | Sale | −51,425 | $15.07 | $775K | 4,062,377 |
| 2025-03-04 | Anzalone Christopher Richard Chief Executive Officer | Option exercise 10b5-1 | +133,333 | $7.75 | $1.0M | 4,073,802 |
| 2025-03-04 | Anzalone Christopher Richard Chief Executive Officer | Sale 10b5-1 | −133,333 | $17.02 | $2.3M | 3,773,802 |
| 2025-03-03 | Anzalone Christopher Richard Chief Executive Officer | Option exercise 10b5-1 | +166,667 | $7.75 | $1.3M | 3,940,469 |
| 2025-03-03 | Anzalone Christopher Richard Chief Executive Officer | Sale 10b5-1 | −166,667 | $18.03 | $3.0M | 3,907,135 |
| 2025-03-03 | Anzalone Christopher Richard Chief Executive Officer | Option exercise · Stock Option (right to buy Common Stock) 10b5-1 | −166,667 | 185,059 | ||
| 2025-03-03 | Anzalone Christopher Richard Chief Executive Officer | Option exercise · Stock Option (right to buy Common Stock) 10b5-1 | −133,333 | 51,726 | ||
| 2025-02-07 | Anzalone Christopher Richard Chief Executive Officer | Grant or award | +9,550 | $20.10 | $192K | 3,773,802 |
| 2025-02-06 | INGRAM DOUGLAS S Director | Grant or award | +38,396 | $20.09 | $771K | 38,396 |
| 2025-01-23 | OLUKOTUN ADEOYE Y Director | Sale 10b5-1 | −959 | $21.00 | $20K | 35,781 |
| 2025-01-07 | O'Brien Patrick COO and General Counsel | Sale 10b5-1 | −8,000 | $19.69 | $158K | 527,201 |
| 2025-01-07 | Myszkowski Kenneth Allen Chief Financial Officer | Sale 10b5-1 | −8,000 | $19.70 | $158K | 465,433 |
| 2025-01-07 | Myszkowski Kenneth Allen Chief Financial Officer | Sale 10b5-1 | −10,000 | $19.69 | $197K | 455,433 |
| 2025-01-06 | Hamilton James C Chief Discovery/Trans Medicine | Sale 10b5-1 | −21,758 | $19.68 | $428K | 283,093 |
| 2025-01-06 | Hamilton James C Chief Discovery/Trans Medicine | Sale 10b5-1 | −10,971 | $20.11 | $221K | 272,122 |
| 2025-01-06 | O'Brien Patrick COO and General Counsel | Sale 10b5-1 | −19,658 | $19.69 | $387K | 544,727 |
| 2025-01-06 | O'Brien Patrick COO and General Counsel | Sale 10b5-1 | −9,526 | $20.10 | $191K | 535,201 |
| 2025-01-06 | Myszkowski Kenneth Allen Chief Financial Officer | Sale 10b5-1 | −17,765 | $19.68 | $350K | 482,835 |
| 2025-01-06 | Myszkowski Kenneth Allen Chief Financial Officer | Sale 10b5-1 | −9,402 | $20.10 | $189K | 473,433 |
Page 6 of 28 · 542 trades